Posted by Michael Wonder on 26 Jul 2026
Celltrion files for European approval of Cosentyx biosimilar CT-P55, accelerating push into key global markets
24 July 2026 - Celltrion said Friday it has submitted a marketing authorization application to the EMA for CT-P55, its biosimilar of the auto-immune disease treatment Cosentyx (secukinumab).
The application covers all indications approved for the reference product in Europe, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
